Immuneering (NASDAQ:IMRX) and Alkermes (NASDAQ:ALKS) Head-To-Head Analysis

Alkermes (NASDAQ:ALKS) and Immuneering (NASDAQ:IMRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Volatility and Risk

Alkermes has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500.

Valuation and Earnings

This table compares Alkermes and Immuneering”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.51 billion	3.87	$355.76 million	$2.17	16.59
Immuneering	$320,000.00	180.48	-$53.47 million	($1.97)	-0.94

Alkermes has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Immuneering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	22.15%	24.92%	14.55%
Immuneering	N/A	-79.19%	-69.08%

Insider & Institutional Ownership

95.2% of Alkermes shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 4.9% of Alkermes shares are held by insiders. Comparatively, 25.0% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Alkermes and Immuneering, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	2	9	0	2.67
Immuneering	1	3	4	0	2.38

Alkermes presently has a consensus price target of $37.08, suggesting a potential upside of 3.01%. Immuneering has a consensus price target of $12.20, suggesting a potential upside of 555.91%. Given Immuneering’s higher possible upside, analysts plainly believe Immuneering is more favorable than Alkermes.

Summary

Alkermes beats Immuneering on 11 of the 14 factors compared between the two stocks.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.